Contact
searchSearch
HMP Global
Login

Breast Cancer

Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Tiffany Traina, MD
Videos
Optimizing Checkpoint Inhibitor Use Across Early-Stage and Metastatic Triple-Negative Breast Cancer
10/30/2026
Tiffany A. Traina, MD
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...
Tiffany Traina, MD, discusses...
10/30/2026
Oncology
Sara Nunnery, MD
Videos
Oral SERDs and ESR1 Mutation Monitoring Reshape Treatment of HR-Positive Metastatic Breast Cancer
10/30/2026
Sara Nunnery, MD, MS
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...
Sara Nunnery, MD, discusses...
10/30/2026
Oncology
Seth Wander, MD, PhD
Videos
Next-Generation Endocrine Therapies Reshape Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer
10/30/2026
Seth Wander MD, PhD
Seth Wander, MD, PhD, discusses advances in endocrine therapy for ER-positive, HER2-negative metastatic breast cancer, highlighting emerging oral SERDs, ESR1 mutation testing, ctDNA-guided treatment strategies from SERENA-6, and novel...
Seth Wander, MD, PhD, discusses advances in endocrine therapy for ER-positive, HER2-negative metastatic breast cancer, highlighting emerging oral SERDs, ESR1 mutation testing, ctDNA-guided treatment strategies from SERENA-6, and novel...
Seth Wander, MD, PhD, discusses...
10/30/2026
Oncology
Sara Hurvitz, MD
Videos
Gedatolisib-Based Therapy Improves Progression-Free Survival in PIK3CA Wild-Type Advanced Breast Cancer
10/01/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer following...
Sara Hurvitz, MD, discusses...
10/01/2026
Oncology
Paolo Tarantino, MD, PhD
Videos
Long-Term Results Support De-escalated Neoadjuvant Therapy in HER2-Positive Breast Cancer
07/22/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD,...
07/22/2026
Oncology
Komal Jhaveri, MD
Videos
Vepdegestrant Improves Outcomes in ESR1-Mutant ER-Positive Metastatic Breast Cancer
06/29/2026
Komal Jhaveri, MD
Komal Jhaveri, MD, discusses results from the phase 3 VERITAC-2 trial which demonstrated that vepdegestrant improved progression-free survival in patients with ESR1-mutant ER-positive, HER2-negative metastatic breast cancer, supporting its...
Komal Jhaveri, MD, discusses results from the phase 3 VERITAC-2 trial which demonstrated that vepdegestrant improved progression-free survival in patients with ESR1-mutant ER-positive, HER2-negative metastatic breast cancer, supporting its...
Komal Jhaveri, MD, discusses...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology
Kevin Kalinsky, MD
Videos
Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer
06/24/2026
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...
Kevin Kalinsky, MD, discusses...
06/24/2026
Oncology

Recent News

News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
Petosemtamab Plus Pembrolizumab Significantly Improves Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3...
10/30/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Demonstrates 59% Response Rate in Platinum-Resistant Ovarian Cancer
10/30/2026
Stephanie Holland
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA...
10/30/2026
Oncology
News
Updated ASTRO Guidelines Expand Role of Hypofractionated Radiotherapy in Localized Prostate Cancer
10/30/2026
Stephanie Holland
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice...
10/30/2026
Oncology
News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use